TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01743521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/PEG-IFN/RBV
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/PEG-IFN/RBV
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/PEG-IFN/RBV
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
Study: NCT03080662

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ORYGEN DUAL Sham Valve
Description: Training of the inspiratory muscles during 5 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORYGEN DUAL Valve
Description: Training of the inspiratory muscles during 5 weeks
Study: NCT00611715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: OSI-774 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: OSI-774 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg/day

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: To determine HER2 gene amplification or excess copies of the HER2 gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: To determine HER2 gene amplification or excess copies of the HER2 gene

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: to measure the epidermal growth factor receptors (EGFR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: to measure the epidermal growth factor receptors (EGFR)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Study: NCT02137577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB catheter
Description: DEB catheter (trade name: Litos/Tulip)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: common PTA balloon catheter
Description: common PTA balloon catheter
Study: NCT01016418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum powder
Description: Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
Study: NCT03510806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: dietary supplement contain protein from milk and fruit extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: color, taste, and calorie-matched placebo
Study: NCT00595647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent
Description: Implantation of stent

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare metal stent
Description: Implantation of stent
Study: NCT03783858

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: OCT images
Study: NCT02259062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music with brief mindfulness intervention
Description: Music listening with mindfulness therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music listening alone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Audiobook listening
Study: NCT04191148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01
Description: crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringers Solution for Injection dosed BID by intraurethral administration
Study: NCT00345800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (Xyrem)
Description: * Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral
Study: NCT01470729

Intervention type: OTHER
Intervention: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
Description: MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples

Intervention type: OTHER
Intervention: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
Description: MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples

Intervention type: OTHER
Intervention: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
Description: MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples

Intervention type: OTHER
Intervention: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
Description: MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
Study: NCT00078728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Anxiety Prevention Program
Description: Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation only
Description: Participants will undergo evaluations without active treatment for 8 weeks.
Study: NCT01325597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention
Study: NCT02726035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: oral naltrexone 50 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: oral naltrexone 50 mg daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo (appearing identical to naltrexone) once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo (appearing identical to naltrexone) once daily
Study: NCT03723122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Communication Reinforcement Intervention
Description: Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
Study: NCT03740477

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
Study: NCT00913068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse Abdominal Plan (TAP)
Description: An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard post op pain control
Description: opiates
Study: NCT03121495

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Second forward view (SFV) examination of the right colon
Description: The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
Study: NCT02107742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal speed lidocaine injection
Description: 30 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow lidocaine injection
Description: speed 45 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast lidocaine injection
Description: speed 15 seconds
Study: NCT02874573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Investigational agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT01799109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate & albuterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium
Study: NCT01849445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physiotherapy
Description: Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home physiotherapy exercises
Description: Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
Study: NCT02282306

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TTIP-PRO
Description: The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
Study: NCT03493568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Description: switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg plus one RTI
Description: Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
Study: NCT00644956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
Study: NCT01340300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Two supervised exercise sessions per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Two supervised exercise sessions per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin QD for two weeks, then BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin QD for two weeks, then BID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational information
Description: educational information
Study: NCT01043445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GPR 119 agonist, 2-oleyl glycerol
Description: Emulgation, 50 ml. containing 2g 2OG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oleic acid
Description: Emulgation, 50 ml. containing 1.54g of oleic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Study: NCT04889859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long Roux limb Roux-en-Y reconstruction
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long biliopancreatic limb Roux-en-Y reconstruction
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
Study: NCT00721032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI guided VT ablation
Description: Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Increased dose of amiodarone
Description: Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD
Study: NCT02215954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999169
Description: FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999169
Description: FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niflec
Description: Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
Study: NCT03409562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor control training
Description: Exercises to strengthen the lumbar musculature and control the posture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor control training
Description: Exercises to strengthen the lumbar musculature and control the posture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain neurophysiology education
Description: Educational sessions to improve patient's neurophysiology of pain knowledge.
Study: NCT00585975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution
Description: sterile opthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution
Description: sterile opthalmic solution
Study: NCT00726713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx (a medical food)
Description: Metanx one tablet twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metanx placebo
Description: Metanx placebo one tablet twice a day
Study: NCT00376012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
Study: NCT04456712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 MG/200 ML Intravenous Solution
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 MG/200 ML Intravenous Solution
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 MG
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 MG
Description: antibiotic
Study: NCT00498615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fasudil
Description: Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
Study: NCT04540562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD app
Description: The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.